Lifeboat Foundation

Older adults with more severe behavioral symptoms, including agitation, aggression, and disinhibition, are more likely to become divorced than those with less severe symptoms. However, increasing stages of dementia are associated with a low likelihood of divorce. These are some of the conclusions of a new study published August 16 in the open-access journal PLOS ONE by Joan Monin of the Yale School of Public Health and colleagues.

In recent years, divorce has been on the rise among older adults. Moreover, dementia can be difficult for married couples for many reasons, including the introduction of caregiving burden, loss of intimacy, and financial strain.

In a new study, researchers analyzed data from 37 NIA/NIH Alzheimer’s Disease Research Centers (ADRCs) across the US. The final study included 263 married or living-as–married couples who were divorced or separated during their follow up period at an ADRC, as well as 1,238 age-matched controls.

Google DeepMind researchers have finally found a way to make life coaching even worse: infuse it with generative AI.

According to internal documents obtained by The New York Times reports, Google and the Google-owned DeepMind AI lab are working with “generative AI to perform at least 21 different types of personal and professional tasks.” And among those tasks, apparently, is an effort to use generative AI to build a “life advice” tool. You know, because an inhuman AI model knows everything there is to know about navigating the complexities of mortal human existence.

As the NYT points out, the news of the effort notably comes months after AI safety experts at Google said, back in just December, that users of AI systems could suffer “diminished health and well-being” and a “loss of agency” as the result of taking AI-spun life advice. The Google chatbot Bard, meanwhile, is barred from providing legal, financial, or medical advice to its users.

Graphene nanoribbons have outstanding properties that can be precisely controlled. Researchers from Empa and ETH Zurich, in collaboration with partners from Peking University, the University of Warwick and the Max Planck Institute for Polymer Research, have succeeded in attaching electrodes to individual atomically precise nanoribbons, paving the way for precise characterization of the fascinating ribbons and their possible use in quantum technology.

Quantum technology is promising, but also perplexing. In the coming decades, it is expected to provide us with various technological breakthroughs: smaller and more precise sensors, highly secure communication networks, and powerful computers that can help develop new drugs and materials, control financial markets, and predict the weather much faster than current computing technology ever could.

To achieve this, we need so-called quantum materials: substances that exhibit pronounced quantum physical effects. One such material is graphene. This two-dimensional structural form of carbon has unusual physical properties, such as extraordinarily high tensile strength, thermal and electrical conductivity—as well as certain quantum effects. Restricting the already two-dimensional material even further, for instance, by giving it a ribbon-like shape, gives rise to a range of controllable quantum effects.

DURHAM – A big licensing deal potentially worth hundreds of millions of dollars with an Austrlia-based company at the same time also has triggered what Precision Biosciences calls a “right-sized” organization of the company.

“Prior to the announcement, we had 190 employees, with 110 going forward with Precision. Most of the 80 employees went with Imugene, with the remainder parting ways with a reduction in force,” Mei Burris, director of investor relations and finance for the company,” told WRAL TechWire.

What “right-sized” means was not immediately explained in the company’s announcement Tuesday night after the markets closed. The company’s stock is trading at under $1 and it lost $12 million in its most recent quarter ending June 30.

Not many pure-play quantum computing start-ups have dared to go public. So far, the financial markets have tended to treat the newcomers unsparingly. One exception is IonQ, who along with D-Wave and Rigetti, reported quarterly earnings last week. Buoyed by hitting key technical and financial goals, IonQ’s stock is up ~400% (year-to-date) and CEO Peter Chapman is taking an aggressive stance in the frothy quantum computing landscape where error correction – not qubit count – has increasingly taken center stage as the key challenge.

This is all occurring at a time when a wide variety of different qubit types are vying for dominance. IBM, Google, and Rigetti are betting on superconducting-based qubits. IonQ and Quantinuuum use trapped ions. Atom Computing and QuEra use neutral atoms. PsiQuantum and Xanadu rely on photonics-based qubits. Microsoft is exploring topological qubits based on the rare Marjorana particle. And more are in the works.

It’s not that the race to scale up qubit-count has ended. IBM has a 433-plus qubit device (Osprey) now and is scheduled to introduce 1100-qubit device (Condor) late this year. Several other quantum computer companies have devices in the 50–100 qubit range. IonQ’s latest QPU, Forte, has 32 qubits. The challenge they all face is that current error rates remain so high that it’s impractical to reliably run most applications on the current crop of QPUs.

Watch the full episode and view show notes here: https://bit.ly/3Oo9mE5
Become a member to receive exclusive content: https://peterattiamd.com/subscribe/
Sign up to receive Peter’s email newsletter: https://peterattiamd.com/newsletter/

In this “Ask Me Anything” (AMA) episode, Peter delves into the realm of genetics, unraveling its connection to disease and emphasizing the value of understanding one’s genetic risks. He elucidates essential background knowledge on genetics before delving into the myriad reasons why individuals might consider genetic testing. Peter differentiates scenarios where genetic testing provides genuine insights from those where it may not be as useful. From there, Peter explores a comprehensive comparison of commercial direct-to-consumer genetic tests, providing insights on interpreting results and identifying the standout options for gaining insights into personal health.

Continue reading “Genetics: how they impact disease risk, what you can do about it, testing & more [AMA 50 sneak peek]” »

OpenAI, the artificial intelligence studio that popularised AI with its chatbot ChatGPT, is reportedly facing a financial crisis that could lead to its bankruptcy.

According to a report by Analytics India Magazine, OpenAI spends a staggering $700,000 every day to run ChatGPT, one of its flagship AI services. The chatbot, which uses a powerful language model called GPT, can generate realistic and engaging conversations on various topics.

Cyrus Hodes alleges that CEO Emad Mostaque deceived him into selling his 15% stake for $100—three months before the startup reached a $1 billion valuation. His stake would be worth over $500 million now.

Mostaque convinced Hodes “that the company he had helped build was essentially worthless,” leading him to sell his shares to him in October 2021 and May 2022, according to a complaint filed in San Francisco federal court on July 13.

“But just a few months later, in August 2022, the company engaged in a seed funding round in which venture capital firms invested $101 million at a post-money valuation of $1 billion,” the complaint states. “More recently, the company has been in the marketplace seeking funding at a valuation of $4 billion.”

Please check out Numerai — our sponsor using our link @
http://numer.ai/mlst.

Numerai is a groundbreaking platform which is taking the data science world by storm. Tim has been using Numerai to build state-of-the-art models which predict the stock market, all while being a part of an inspiring community of data scientists from around the globe. They host the Numerai Data Science Tournament, where data scientists like us use their financial dataset to predict future stock market performance.

Continue reading “Counterfeit People. Daniel Dennett. (Special Edition)” »